PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.
Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity, precluding any further drug development.